

Dear Colleagues,

We are pleased to invite you to participate in the **INFACTS study** (*Real-life comparative effectiveness of calcineurin inhibitors and JAK inhibitors in steroid-refractory acute severe ulcerative colitis previously exposed to infliximab*), trying to address a critical knowledge gap: the comparative effectiveness of JAK inhibitors versus calcineurin inhibitors as rescue therapy in ASUC patients who have been previously exposed to infliximab.

Study Overview

Design: Multicenter retrospective study (January 2016 – December 2025)

Population: Consecutive ASUC patients hospitalized for steroid-refractory disease, previously exposed to infliximab, and treated with JAK inhibitors or calcineurin inhibitors as rescue therapy

What We Ask

Participating centers will identify eligible patients and complete a standardized REDCap eCRF with routinely collected clinical data (demographics, treatment details, outcomes at discharge, 3 and 12 months, last follow-up).

Centers meeting enrollment targets will be offered co-authorship opportunities.

How to Participate

For more information or to express your interest, please contact:

Dr. Giuseppe Privitera – giuseppe.privitera@humanitas.it

We look forward to your participation in this important ECCO-endorsed collaborative study.

Sincerely,

The INFACTS Study Team – dr Giuseppe Privitera, Prof Davide Laharie, Prof Alessandro Armuzzi